

## **Solid Tumors & Quantitative Oncology Programs' Joint Retreat**

*Program Committee: Paul Spellman, Adam Margolin, Molly Kulesz-Martin, Shannon McWeeney*

**7:30~8:00 Registration and breakfast, 10<sup>th</sup> Floor: 5<sup>th</sup> Avenue ABC Room**

8:00~8:15 Welcome/Introduction: *Paul Spellman*

### **Signaling, Imaging of Solid Tumor Response**

*Session Chair Adam Margolin*

8:15~8:40 *Laura Heiser, Ph.D.* - The Library of Integrated Network-based Cellular Signatures (LINCS) for discovery of cell responses that aid in the development of new therapies

8:40~9:05 *Rosalie Sears, Ph.D.* - Translation of basic discovery targeting Myc to clinical trials in breast and pancreatic tumors

9:05~9:30 *James Galbraith & Catherine Galbraith* - High resolution/functional imaging

### **Targeting Mechanisms/Preclinical Inhibitor Screens**

*Session Chair Adam Margolin*

9:30~9:55 *Joshi Alumkal, M.D.* - (Epi)genomics to discover resistance mechanisms in prostate cancer

9:55~10:20 *Molly Kulesz-Martin, Ph.D.* - Patient-specific treatment discovery in head and neck squamous cell carcinoma

### **10:20~10:35 Break**

10:35~11:00 *Shannon McWeeney, Ph.D.* - Mining disease specific large datasets (The Cancer Genome Atlas and others) and functional cross analysis

### **Early Detection, Response Monitoring and Computational Tools** *Session Chair Molly Kulesz-Martin*

11:00~11:25 *Wei Huang, M.D.* - Functional MRI approaches to tumor characterizations

11:25~11:50 *Matthew Taylor, M.D.* - Defining obstacles and optimizing discovery from clinical trials

11:50~12:15 *Adam Margolin, Ph.D.* - Computational solutions to tumor characterizations

12:15~12:30 *Judy Barkal* - Overview of the data inventory

### **12:30~2:15 Lunch & Break-out – Pilot Project Pitch Talk – 3<sup>rd</sup> Floor: Lipman Wolfe Room**

**Workshop** for Knight Solid Tumors/Quantitative Oncology New Collaborations Award, \$50K pilot  
*Breakout areas available: 10<sup>th</sup> Floor: 5<sup>th</sup> Avenue ABC Room, 3<sup>rd</sup> Floor: Lipman Wolfe Room & Wendel Conference Room*

### **Return to 10<sup>th</sup> Floor: 5<sup>th</sup> Avenue ABC Room**

### **Pilot Project Presentations and Interactive Feedback**

*Session Chair Paul Spellman*

2:15~2:45 Signaling, imaging of solid tumor response - Pitch Talks  
Discussion provocateurs: *Alex Guimaraes, Tomasz Beer*

2:45~3:15 Targeting mechanisms/preclinical inhibitor screens - Pitch Talks  
Discussion provocateurs: *Charles Thomas, Theresa Koppie*

### **3:15~3:30 Break**



## **Solid Tumors & Quantitative Oncology Programs' Joint Retreat**

*Program Committee: Paul Spellman, Adam Margolin, Molly Kulesz-Martin, Shannon McWeeney*

3:30~4:00 Early detection and response monitoring - Pitch Talks  
Discussion provocateurs: *Christopher Ryan, Brett Sheppard*

4:00~4:45 *Max Diehn, MD, PhD* - Keynote  
Ultrasensitive Detection of Circulating Tumor DNA by Deep Sequencing

Max Diehn MD, PhD is an Assistant Professor of Radiation Oncology at Stanford University. He has co-appointments in the Stanford Cancer Institute and Institute for Stem Cell Biology and Regenerative Medicine. Dr. Diehn trained at Harvard University and Stanford University and has a background in genomics and stem cell biology. He is a board certified Radiation Oncologist and specializes in the treatment of lung cancer. Dr. Diehn's research program spans basic, translational, and clinical studies. He has made significant contributions in number of areas, including in cancer stem cell biology and cancer genomics. His group recently developed a next generation sequencing-based method for detection of circulating tumor DNA called CAPP-Seq. Further development and clinical application of this approach are major ongoing research efforts in his laboratory.

4:45~6:30 **Reception and Wine Tasting – 1<sup>st</sup> Floor: Red Star Club Room**  
*Drawing winner announced*

### **Knight Solid Tumors/Quantitative Oncology New Collaborations Pilot Award (\$50K)**

Collaboration is necessary to tackle the challenges of integrating quantitative approaches with the treatment of cancer. The Knight Cancer Institute has committed to support this effort with a one year pilot grant of \$50,000 to a team comprised of one member of quantitative oncology and one member of solid tumors. Selection of the pilot awardees will occur in two phases: First, teams will sign up to present a pitch talk in five minutes describing the clinical question and the quantitative approach to solving that problem, about ten pitch talks will be available, first come first serve. Second, Molly Kulesz-Martin, Pepper Schedin, Adam Margolin, and Paul Spellman will select three applications for a full write-up of two pages and will evaluate the proposals to select the winner. Terms of the award are provided (detailed RFP to be provided).